Novel tumor antigen binding agents and uses thereof
AssigneesITM Isotopen Technologien München AG, Paul Scherrer Institut
InventorsMartina Benesova, Cristina Müller, Christoph Umbricht, Roger Schibli, Konstantin Zhernosekov, Luisa Maria Deberle
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds according to General Formula (1)(i) or (1)(ii): wherein A is a diagnostic or therapeutic agent comprising a binding site for a tumor antigen, and the spacer comprises at least one C—N bond.
Claims74
A compound according to General Formula (1)(i) or (1)(ii):
- wherein A is a diagnostic or therapeutic agent comprising a binding site for a tumor antigen, and the spacer comprises at least one C—N bond.
A compound characterized by the following General Formula (1a):
- wherein D is a chelator;
- Tbm is a tumor-antigen binding moiety;
- linker is a linker, preferably comprising a cyclic group or an aromatic group;
- spacer is a spacer comprising a C—N bond;
- and
- a is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
- or a pharmaceutically acceptable salt, ester, solvate or radiolabeled complex thereof.
A radiolabeled complex comprising a radionuclide and a compound according to any one of the preceding claims.
An in vitro method of detecting the presence of cells and/or tissues expressing prostate-specific membrane antigen (PSMA) comprising
- (a) contacting said PSMA-expressing cells and/or tissues with a compound, radiolabeled complex, pharmaceutical composition or kit according to any one of the preceding claims;
- (b) applying detection means, optionally radiographic imaging, to detect of said cells and/or tissues.
Dependencies are inferred from the claim text.